Most vascular cell-culture experiments change one thing at a time. You add a signaling molecule and watch what happens, or you perturb the membrane and watch what happens. Sulfobutylether beta-cyclodextrin platforms make it practical to do both in the same well — and that combination is the entire design premise behind KIMERA-VASC™.
KIMERA-VASC™ is a modular two-component research system that pairs sulfobutylether-β-cyclodextrin (SBE-β-CD) with a researcher-selected peptide. The cyclodextrin component modulates the lipid environment. The peptide component introduces a defined signaling cue. Together they allow an investigator to ask a question that a single-agent experiment cannot: does this signaling response depend on the state of the membrane it is being delivered into?
This article explains what each component is, why the pairing is scientifically interesting, and what the published cyclodextrin and peptide literature actually supports.
What KIMERA-VASC™ Is
KIMERA-VASC™ is not a formulation, a complex, or a delivery vehicle sold as a finished preparation. It is a two-vial research kit: one vial of lyophilized SBE-β-CD, plus one vial of a separately selected lyophilized peptide. The researcher decides whether to use them sequentially, concurrently, or independently.
That modularity is deliberate. A fixed-ratio complex would lock the investigator into one experimental design. Supplying the components separately preserves the ability to run the cyclodextrin arm, the peptide arm, and the combined arm as three distinct conditions — which is how a mechanistic question of this shape should be structured in the first place.
The KIMERA-VASC™ research system is currently configured with a fixed 100 mg SBE-β-CD component and a selectable peptide from the catalog, including GHK, KPV, BPC-157, TB-500, MOTS-c, and Epithalon variants. The SBE-β-CD component is also available on its own for laboratories that only need the cyclodextrin.
Component One: Sulfobutylether-β-Cyclodextrin (SBE-β-CD)
Structure and identity
Cyclodextrins are cyclic oligosaccharides built from α-1,4-linked glucopyranose units. β-cyclodextrin has seven such units arranged in a truncated-cone macrocycle with a hydrophilic exterior and a hydrophobic internal cavity — the structural feature that lets it host non-polar guest molecules.
Sulfobutylether-β-cyclodextrin is a chemically modified derivative. Sulfobutyl groups are attached at the 2-, 3-, and 6-hydroxyl positions across the seven glucopyranose units, with an average degree of substitution near 6.5 in the most widely characterized commercial material (Stella & He / Luke et al., Int J Pharm, 2020). Each sulfobutyl arm terminates in a sodium sulfonate, separated from the cavity by a four-carbon spacer — which is what makes the molecule strongly polyanionic while leaving the hydrophobic cavity functionally intact.
The United States Pharmacopeia lists the material as betadex sulfobutyl ether sodium under CAS 182410-00-0, with the empirical formula C₄₂H₇₀₋ₙO₃₅·(C₄H₈SO₃Na)ₙ and an average molecular weight of 2163 when n = 6.5. Commercial degree of substitution is not a single number but a distribution; the USP range sits between 6.2 and 6.9, and the distribution itself measurably influences guest encapsulation behavior (Pharmaceutics, 2024).
Practical consequence for bench work: SBE-β-CD is a defined mixture of isomers, not a single molecular species. Batch-level analytical characterization matters, which is why every lot is released against third-party COA verification.
Why cyclodextrins became a vascular research tool
The reason cyclodextrins appear so often in vascular papers has nothing to do with solubilization. It has to do with cholesterol.
β-cyclodextrins extract cholesterol from the plasma membrane. Methyl-β-cyclodextrin (MβCD) in particular has been used for decades as the standard pharmacological tool for depleting membrane cholesterol and disrupting cholesterol-rich microdomains — lipid rafts and caveolae. Cholesterol depletion causes invaginated caveolae to disappear (Rodal et al., Mol Biol Cell, 1999), and that structural collapse has direct functional consequences in vascular tissue.
One of the clearest demonstrations comes from isolated rat tail artery: after MβCD treatment, contractile responses to α₁-adrenergic stimulation and membrane depolarization were essentially preserved, while responses to 5-HT, vasopressin, and endothelin fell by more than half, with electron microscopy confirming caveolar disruption (Dreja et al., ATVB, 2002). Receptor-specific dependence on membrane organization is not a subtle effect — it is a sorting mechanism.
The same logic extends to inflammatory endothelial phenotype. MβCD has been shown to reduce monocyte adhesion to endothelial monolayers by downregulating adhesion molecules and caveolae-related proteins and by reorganizing the actin cytoskeleton (Wu et al., Biol Pharm Bull, 2016).
Broader interest in the cyclodextrin class accelerated after work showing that 2-hydroxypropyl-β-cyclodextrin dissolved cholesterol crystals and promoted plaque regression in murine models through oxysterol-mediated, LXR-dependent macrophage reprogramming (Zimmer et al., Sci Transl Med, 2016). More recent clinical-sample work has continued to examine cyclodextrin effects on cholesterol crystal handling by circulating monocytes (PLOS ONE, 2025). These findings are cited here as literature context explaining why the reagent class is studied — not as properties of, or claims about, any Kimera Chems product.
Why SBE-β-CD instead of methyl-β-cyclodextrin
This is the most important design decision in the platform, and it is worth being precise about.
MβCD is an aggressive cholesterol acceptor. That is exactly the problem. A dedicated comparison in bovine pulmonary artery endothelial cells found that both MβCD and hydroxypropyl-β-cyclodextrin produced significant membrane cholesterol loss but also cytotoxicity, morphological change, actin cytoskeletal reorganization, altered membrane fatty acid composition, and reduced trans-endothelial electrical resistance (Hinzey et al., Indian J Biochem Biophys, 2012). The same group’s protocol chapter states the caution directly: cyclodextrin choice is not a neutral variable in lipid raft studies, because the depleting agent itself can produce the phenotype you are trying to measure.
Unmodified and less aggressive β-cyclodextrins behave differently. In bovine aortic endothelial cells, β-CD did not induce cell death even at the highest concentration tested, and the authors attributed this to it not provoking wholesale cholesterol efflux or complete raft disintegration (Molecules, 2020).
SBE-β-CD sits in a useful place on that spectrum. Its polyanionic sulfobutyl arms substantially change its interaction profile relative to native and methylated β-CD, and it was specifically engineered for a favorable safety profile — it now appears in more than a dozen FDA-approved injectable products as a solubilizer and stabilizer. For a research system where the peptide response is the readout, a cyclodextrin that does not independently wreck the monolayer is the right tool. Investigators should still run cyclodextrin-only controls at every concentration used.
Component Two: The Selectable Peptide
Cyclodextrins and peptides genuinely interact
The second component is not simply “a peptide added alongside a sugar.” Cyclodextrin–peptide interaction is a well-characterized phenomenon and needs to be accounted for in experimental design.
Cyclodextrins can suppress peptide and protein aggregation, generally attributed to their capacity to accommodate exposed hydrophobic residues — particularly aromatic side chains — within the cavity, with additional non-inclusion mechanisms such as surfactant-like surface competition also contributing (Serno et al., Adv Drug Deliv Rev, 2011). Peptides are usually too bulky for full inclusion, so the interaction is typically local rather than whole-molecule encapsulation.
The effect is not universally stabilizing. Work on natively unfolded peptides has reported that cyclodextrins can, in some systems, promote aggregation rather than prevent it (Biochem Biophys Res Commun, 2009). This is a real methodological consideration: reconstitution order, concentration ratio, and incubation time are variables, not details.
Why membrane state changes peptide signaling
The mechanistic payoff of pairing the two components is that peptide receptor signaling is frequently membrane-organization dependent.
Cholesterol-rich microdomains concentrate G protein-coupled receptors and act as assembly platforms for downstream signaling components, and cholesterol can modulate receptor conformation directly (Biochemistry, 2025). A concrete example: activation of the GLP-1 receptor redistributes it into flotillin-containing nanodomains, and MβCD-mediated cholesterol depletion prevented both that redistribution and receptor internalization (Curr Opin Cell Biol, 2021).
That is precisely the class of experiment this platform is built for. If a peptide’s measured effect in an endothelial or smooth muscle model changes when membrane cholesterol is modulated, the response is at least partly raft- or caveolae-dependent. If it does not change, that is informative too.
The available peptide component options span several distinct research literatures — BPC-157 and TB-500 in tissue-repair and endothelial signaling work, GHK and KPV in matrix and inflammatory signaling contexts, and MOTS-c and Epithalon in metabolic and cellular-aging models. Additional background on individual peptides is available in the Kimera Chems peptides blog category.
Research Applications
KIMERA-VASC™ supports in vitro laboratory investigation in areas including:
- Lipid stress modeling — systematically altering membrane cholesterol content in cultured cells using the SBE-β-CD component.
- Signaling pathway interaction — evaluating how a peptide-based signaling cue behaves in a modified lipid environment versus an unmodified one.
- Comparative signaling studies — holding the cyclodextrin arm constant while varying the peptide component to compare biological contexts or competitive signaling interactions.
- Vascular cell assays — application in endothelial and smooth muscle cell models.
- Mechanistic adaptation research — characterizing cellular responses to combined environmental and signaling modification.
- Reagent-control design — using the cyclodextrin-only and peptide-only arms as the internal controls that combined-condition experiments require.
Technical Specifications
| Property | Specification |
|---|---|
| Product name | KIMERA-VASC™ |
| System components | Sulfobutylether-β-cyclodextrin (SBE-β-CD) + selectable peptide |
| Cyclodextrin CAS | 182410-00-0 |
| Cyclodextrin formula | C₄₂H₇₀₋ₙO₃₅·(C₄H₈SO₃Na)ₙ |
| Average molecular weight | 2163 g/mol (n = 6.5) |
| Cyclodextrin quantity | 100 mg lyophilized, 1 vial |
| Peptide component | Selectable; supplied as separate lyophilized vial |
| Platform class | Modular in vitro vascular research system |
| Appearance | Lyophilized powder |
| Analytical verification | Third-party COA verification on both components |
Storage and Handling
- Lyophilized material: store at room temperature, protected from direct light.
- Reconstituted material: refrigerate at 2 to 8 degrees Celsius and use close to preparation.
- Storage of the solid: controlled room temperature, sealed and protected from light. Storage guidance is a house recommendation. Analytical documentation is per-lot release testing.
- Environmental control: keep vials tightly sealed with desiccant to prevent atmospheric moisture accumulation; use opaque containers to protect from light exposure.
- Aseptic technique: use sterile solvents and standard professional laboratory technique for any cell culture preparation.
- Component handling: reconstitute and store the two components separately unless the experimental design specifically requires pre-incubation.
Frequently Asked Questions
Is KIMERA-VASC™ a pre-formed cyclodextrin–peptide complex? No. It is supplied as two separate lyophilized components. Any interaction between them is determined by the researcher’s own protocol.
Why is SBE-β-CD used instead of methyl-β-cyclodextrin? MβCD is a more aggressive cholesterol acceptor and has been documented to produce cytotoxicity and cytoskeletal changes in vascular endothelial cells at concentrations used for depletion. SBE-β-CD was engineered for a more favorable profile.
Can the peptide component be changed? Yes — that is the point of the platform. The cyclodextrin component stays fixed while the peptide varies, which is what makes comparative signaling designs possible.
What analytical documentation is provided? Both components are released against third-party COA verification. Current documentation is maintained in the Kimera Chems COA archive.
References
- Luke DR, Rajewski RA, et al. Sulfobutylether-β-cyclodextrin. International Journal of Pharmaceutics. 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196545/
- United States Pharmacopeia. Betadex Sulfobutyl Ether Sodium monograph. USP–NF. https://doi.usp.org/USPNF/USPNF_M8743_04_01.html
- Effects of degree of substitution and strong-bonded water on SBE-β-CD encapsulation. Pharmaceutics. 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11279665/
- Rodal SK, et al. Extraction of cholesterol with methyl-β-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Molecular Biology of the Cell. 1999. https://www.molbiolcell.org/doi/10.1091/mbc.10.4.961
- Dreja K, et al. Cholesterol depletion disrupts caveolae and differentially impairs agonist-induced arterial contraction. Arteriosclerosis, Thrombosis, and Vascular Biology. 2002. https://www.ahajournals.org/doi/10.1161/01.ATV.0000023438.32585.A1
- Wu L, et al. Methyl-β-cyclodextrin impairs the monocyte-adhering ability of endothelial cells. Biological & Pharmaceutical Bulletin. 2016. https://pubmed.ncbi.nlm.nih.gov/27251506/
- Hinzey AH, Kline MA, Kotha SR, et al. Choice of cyclodextrin for cellular cholesterol depletion for vascular endothelial cell lipid raft studies. Indian Journal of Biochemistry and Biophysics. 2012. https://pubmed.ncbi.nlm.nih.gov/23259319/
- β-Cyclodextrin inhibits monocytic adhesion to endothelial cells through nitric oxide-mediated depletion of cell adhesion molecules. Molecules. 2020. https://www.mdpi.com/1420-3049/25/16/3575
- Zimmer S, Grebe A, et al. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Science Translational Medicine. 2016. https://www.science.org/doi/10.1126/scitranslmed.aad6100
- Lübbering N, et al. Cyclodextrin reduces cholesterol crystal uptake by circulating monocytes in patients undergoing coronary angiography. PLOS ONE. 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12747169/
- Serno T, Geidobler R, Winter G. Protein stabilization by cyclodextrins in the liquid and dried state. Advanced Drug Delivery Reviews. 2011. https://www.sciencedirect.com/science/article/abs/pii/S0169409X11002262
- Cyclodextrins promote protein aggregation posing risks for therapeutic applications. Biochemical and Biophysical Research Communications. 2009. https://www.sciencedirect.com/science/article/abs/pii/S0006291X09012200
- Effects of membrane cholesterol on the structure and function of selected class A GPCRs. Biochemistry. 2025. https://pubs.acs.org/doi/10.1021/acs.biochem.5c00145
- Mechanisms of selective G protein–coupled receptor localization and trafficking. Current Opinion in Cell Biology. 2021. https://www.sciencedirect.com/science/article/abs/pii/S0955067421000363
Research Use Disclaimer
Research Use Only Disclaimer: This product is developed and distributed strictly as a Research Use Only (RUO) laboratory platform intended exclusively for non-clinical analytical and scientific investigation. It is not an FDA-approved drug, medical device, veterinary product, or household item, and is strictly prohibited for human or animal consumption. Kimera Chems supplies these research systems solely to qualified researchers in institutional settings. Literature cited in this article describes published findings on cyclodextrins and peptides as chemical classes and does not describe, imply, or represent any property, performance, or intended use of any Kimera Chems product.
